A single-course treatment using a CRISPR adenine base editor encapsulated in lipid nanoparticles achieves liver-selective inactivation of ANGPTL3. In nonhuman primates, a single dose led to a greater than 90 percent reduction in circulating ANGPTL3 protein, with durability confirmed up to three year